Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Oncology ; (12): 369-372, 2007.
Artigo em Chinês | WPRIM | ID: wpr-255641

RESUMO

<p><b>OBJECTIVE</b>To investigate the feasibility of 9Tc(m)-HL91 imaging in prediction of 34 radiotherapy sensitivity of naqsopharyngeal cancer( NPC) and its relationship with prognosis.</p><p><b>METHODS</b>patients with NPC confirmed by pathology, staging from II-IVa, underwent 99Tc(m)-HL91 SPECT imaging one week before radiotherapy. 18 of them received adjuvant chemotherapy. The hypoxia in primary nasopharyngeal lesions and cervical lymph node metastases were calculated semi-quantitatively, and compared with clinical findings in medium-term therapy at 4 months and 1 year post therapy.</p><p><b>RESULTS</b>(1) There was no significant relationship between the total preliminary curative effect of adjuvant chemotherapy and the degree of nasopharyngeal lesion hypoxia (T/Mu, gamma = -0.394, P = 0.145; T/ Ce gamma = -0.510, P = 0.052). But there was a significant difference between the partial curative effect group and significant curative effect group. (2) The degree of NPC regression in the medium-term radiotherapy group was negatively correlated with the degree of hypoxia (T/Mu, gamma = -0.602; T/Ce, gamma = -0.643, P < 0.01). (3) 23 patients had good local control except one case with lung and bone metastasis 4 months post-therapy. The lesions disappeared or not developed in 6 patients (T/Mu 1.30 +/- 0.23, T/Ce 3.61 +/- 0.84). Two patients at stage III and IVa relapsed (T/Mu were 1.40 and 1.27, respectively; T/Ce were 4.10 and 3.85, respectively), there was no significant difference. (4) The degree of lymph node hypoxia had no correlation with the curative effect on medium-term radiotherapy.</p><p><b>CONCLUSION</b>99 Tc(m)-HL91 hypoxia imaging may predict sensitivity to radiotherapy in patients with NPC, with a potential help to carry out individual therapy. However, further investigation is needed to ascertain whether it could predict the long-time curative effect on NPC radiotherapy.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Quimioterapia Adjuvante , Seguimentos , Hipóxia , Metástase Linfática , Neoplasias Nasofaríngeas , Diagnóstico por Imagem , Tratamento Farmacológico , Radioterapia , Estadiamento de Neoplasias , Compostos de Organotecnécio , Oximas , Aceleradores de Partículas , Cuidados Pré-Operatórios , Métodos , Prognóstico , Radioterapia de Alta Energia , Indução de Remissão , Reprodutibilidade dos Testes , Tomografia Computadorizada de Emissão de Fóton Único
2.
Chinese Journal of Oncology ; (12): 180-182, 2005.
Artigo em Chinês | WPRIM | ID: wpr-331196

RESUMO

<p><b>OBJECTIVE</b>To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis.</p><p><b>METHODS</b>Forty-eight patients with breast cancer with multi-bone metastases were randomly divided into three groups:15 patients received (188)Re-HEDP (group A), 15 patients received pamidronate (group B) and 18 patients were treated by (188)Re-HEDP plus pamidronate (group C).</p><p><b>RESULTS</b>The overall pain relief rate was 73.3%, 80.0%, 100.0% in groups A, B and C. The response rate of bone metastasis was 40.0%, 33.3%, 66.7% in groups A, B and C respectively. The therapeutic effect of group C was better than those of groups A and B (P < 0.05), without any significance in the difference (P > 0.05).</p><p><b>CONCLUSION</b>The therapeutic effect of (188)Re-HEDP combined with pamidronate for breast cancer with bone metastasis is remarkable in bone pain relief and bone metastasis control, which is better than either (188)Re-HEDP or pamidronate alone.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Antineoplásicos , Usos Terapêuticos , Neoplasias Ósseas , Terapêutica , Neoplasias da Mama , Tratamento Farmacológico , Patologia , Radioterapia , Antígeno Carcinoembrionário , Sangue , Terapia Combinada , Difosfonatos , Usos Terapêuticos , Ácido Etidrônico , Usos Terapêuticos , Seguimentos , Compostos Organometálicos , Usos Terapêuticos , Dor , Manejo da Dor , Radioisótopos , Usos Terapêuticos , Rênio , Usos Terapêuticos
3.
Chinese Journal of Urology ; (12)2001.
Artigo em Chinês | WPRIM | ID: wpr-676025

RESUMO

Objective To evaluate the efficacy and safety of acute ureteroscopy for the treatment of ureterie stones during middle and late pregnancy.Methods From June 1998 to March 2005,17 pregnant women(mean age,27 years;age range,21-35 years)with ureteric stones were treated by ureteroscopy when the fetus was at 20-36 weeks of gestation(mean,29 weeks).All the cases presented with urgent symptoms such as recurrent renal colic(11 cases),fever(4)or acute obstructive anuria(2).Among 17 cases,the stones(between 6 mm?7 mm and 13 mm?21 mm)were located in the upper(8 cases),middle(5)or lower ureter(4);and on the left side(5 eases),on the right(10)and on both(2)of the lower ureter. Mild hydronephrosis were observed in 6 cases and moderate hydronephrosis in 11,Of the 17 cases,14 under- went ureteroscopic pneumatic lithotripsy;in 1 case the calculi were pushed to the renal pelvis;and 2 cases were treated by Double-J catheter drainage.Results All the urgent symptoms in 17 cases were relieved after treatment.The stone-free rate of initial treatment was 82.4%(14 of 17).Three cases with residual stones were treated by Douhle-J catheters,which were replaced every 3 months until the calculi were re- moved.No abortion,premature delivery or complications such as ureter perforation occurred.Mild renal colic occurred in 1 case after insertion of Douhle-J catheter,and it was relieved 3d later;gross hematuria occurred in l case and disappeared 6 d later without treatment.All 17 patients had normal delivery and gave birth to healthy children.Conclusions Ureteroscopy is a safe and reliable method for the treatment of ureteric calculi during middle and late pregnancy.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA